news
Gilead Sciences to acquire Pharmasset, Inc. for $11 billion
21 November 2011 | By Gilead Sciences
Gilead Sciences, Inc., will acquire Pharmasset, Inc., for $137 per share in cash...
List view / Grid view
Gilead Sciences
news
Gilead Sciences finalizes agreement with Tibotec Pharmaceuticals
15 November 2011 | By Gilead Sciences
Gilead Sciences, Inc. has entered into a license agreement with Tibotec Pharmaceuticals...
news
Positive five-year data showing effect of Viread(R) on liver fibrosis and cirrhosis caused by Chronic Hepatitis B
5 November 2011 | By
New long-term data show no development of resistance...
news
Bristol-Myers Squibb and Gilead Sciences announce licensing agreement
26 October 2011 | By Bristol-Myers Squibb Company
Licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination...
news
Gilead and GlobeImmune announce license and collaboration agreement to develop therapeutic vaccine products
24 October 2011 | By Gilead Sciences Inc
Gilead & GlobeImmune enter into an exclusive worldwide license & collaboration agreement...
news
Gilead and Boehringer Ingelheim sign license agreement for novel HIV non-catalytic integrase inhibitors
5 October 2011 | By Gilead Sciences
Gilead Sciences, Inc. and Boehringer Ingelheim have entered into a licensing agreement...
news
European CHMP adopts positive opinion for Eviplera(R)
23 September 2011 | By Gilead Sciences, Inc.
CHMP, has adopted a positive opinion on the company's Marketing Authorisation Application for the once-daily single-tablet regimen, Eviplera(R)...
news
Gilead to make changes in hepatitis C drug trial design
5 September 2011 | By Gilead Sciences, Inc.
Change does not affect ongoing "All Oral" clinical trials evaluating multiple direct-acting antivirals in combination...
news
Gilead’s investigational antiretroviral Quad regimen meets 48-week primary objective in pivotal Phase 3 Clinical Study 102
15 August 2011 | By Gilead Sciences
Phase 3 clinical trial met its primary objective...
news
U.S. FDA approves Gilead Sciences’ Complera™
10 August 2011 | By Gilead Sciences Inc
A new complete once-daily, single-tablet regimen for HIV-1 infection in treatment-naïve adults...
news
Gilead Sciences to purchase biologics process research and clinical manufacturing facility from Genentech
8 August 2011 | By Gilead Sciences Inc
Gilead Sciences, Inc. has signed a definitive agreement...
news
Gilead expands access program for medications in developing world
12 July 2011 | By Gilead Sciences
Gilead Sciences, Inc. announced an expansion of its global access program...
news
Gilead Sciences announces agreement with Tibotec Pharmaceuticals
28 June 2011 | By Gilead Sciences, Inc.
Development and commercialization of a new fixed-dose antiretroviral combination product...
news
Gilead Sciences’ Kevin Young appointed a Commander of The British Empire
13 June 2011 | By Gilead Sciences, Inc.
Gilead Sciences, Inc. is pleased to announce that Kevin Young, has been appointed a Commander of The British Empire...
news
Gilead extends its funding support for the Gilead Sciences Research Centre
5 May 2011 | By Gilead Sciences, Inc.
Gilead Sciences, Inc. has extended its funding support of the Gilead Sciences Research Centre at the Institute of Organic Chemistry and Biochemistry (IOCB) in Prague...
